In recent years, Democratic commissioners at the U.S. Federal Trade Commission (FTC) have clashed with their Republican counterparts over the agency’s standards for large biopharma transactions. Now that they’ve come into power under the Biden administration, the Democrats have launched a sweeping review that threatens to clamp down on industry deal-making. One influential biopharma analyst disagrees with the FTC’s stated reasoning for implementing tougher reviews. In fact, the new stance could be counterproductive, he argued.
Read the full article: Do Pharma Buyouts Hurt Innovation and Lead to Higher Prices? Analyst Hits Back at FTC’s Push For Tougher Reviews //
Source: https://www.fiercepharma.com/pharma/large-pharma-m-as-hurt-innovation-drug-price-analyst-counter-ftc-s-arguments-for-stricter